



Press Release, April 16, 2009

## **Diamyd discussing potential consolidation of Phase III trials**

*Diamyd Medical is conducting two clinical Phase III trials of the Diamyd® diabetes vaccine in children and adolescents with recent onset type 1 diabetes: one in the US and one in nine European countries. In parallel the company is discussing with the regulatory agencies about combining the two trials into one global trial.*

In addition to reducing costs, combining the trials would mean that countries with the fastest rate of patient recruitment could contribute to the greatest extent. The Phase III program encompasses ten countries: Italy, Finland, France, the Netherlands, Slovenia, Spain, the UK, Sweden, Germany and the US. The plan is for the global trial to serve as the basis for market approval in both Europe and the US. Diamyd Medical's continued intention is to report Phase III data during the fourth quarter of 2010.

Patient recruitment is growing sharply at present, as more clinics are being added. There are currently 74 active recruiting clinics in the US and Europe, 34 of which have joined since the beginning of the year.

"We estimate that the expanded number of clinics will enable us to screen 100 children and adolescents in April," says **Elisabeth Lindner, President and CEO** of Diamyd Medical.

### **For additional information, please contact:**

Elisabeth Lindner, President and CEO Diamyd Medical AB (publ.)  
Tel: +46 (0)8 6610026

### **For pictures and press material, please contact:**

Alexandra Fleetwood, Director Communications Diamyd Medical AB (publ.),  
alexandra.fleetwood@diamyd.com  
Tel: +46 (0)8 661 0026

### **About Diamyd Medical**

Diamyd Medical is a Swedish biopharmaceutical company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company's most advanced project is the GAD-based drug Diamyd® for type 1 diabetes. Phase III trials for this drug are in progress in both the US and Europe. In addition, the Company has initiated clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System. The Company has also out-licensed the use of GAD for the treatment of Parkinson's disease.

Diamyd Medical has offices in Sweden and in the US. Shares are listed on the OMX Stockholm Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available on the company's website; [www.diamyd.com](http://www.diamyd.com).

*This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements.*

### **Diamyd Medical AB (publ.)**

Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46 8 661 63 68

E-mail: [info@diamyd.com](mailto:info@diamyd.com). VAT no: SE556530-142001.

([www.omxnordicexchange.com](http://www.omxnordicexchange.com) ticker: DIAM B; [www.otcqx.com](http://www.otcqx.com) ticker: DMYDY)